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Abstract
Background: Concern lingers that dialysis therapy at for-profit (versus not-for-profit)
hemodialysis facilities in the United States may be associated with higher mortality, even though 4
of every 5 contemporary dialysis patients receive therapy in such a setting.
Methods: Our primary objective was to compare the mortality hazards of patients initiating
hemodialysis at for-profit and not-for-profit centers in the United States between 1998 and 2003.
For-profit status of dialysis facilities was determined after subjects received 6 months of dialysis
therapy, and mean follow-up was 1.7 years.
Results: Of the study population (N = 205,076), 79.9% were dialyzed in for-profit facilities after 6
months of dialysis therapy. Dialysis at for-profit facilities was associated with higher urea reduction
ratios, hemoglobin levels (including levels above 12 and 13 g/dL [120 and 130 g/L]), epoetin doses,
and use of intravenous iron, and less use of blood transfusions and lower proportions of patients
on the transplant waiting-list (P < 0.05). Patients dialyzed at for-profit and at not-for-profit facilities
had similar mortality risks (adjusted hazards ratio 1.02, 95% CI 0.99–1.06, P = 0.143).
Conclusion: While hemodialysis treatment at for-profit and not-for-profit dialysis facilities is
associated with different patterns of clinical benchmark achievement, mortality rates are similar.
Background
The incidence rate of treated end-stage renal disease
(ESRD) has increased fourfold in the last quarter century
[1]. In 2003, the cost to the US Medicare program for a
typical dialysis patient was estimated at $67,000 and
ESRD accounted for 6.7% of all Medicare expenditures,
compared with 4.8% in 1991 [1]. Reimbursement for
dialysis services, which has changed little since 1982, is
delivered on a per-treatment basis, irrespective of medical,
logistical, and infrastructure complexities; cost contain-
ment has been a concern since the early days of the Medi-
care ESRD program [2]. Not surprisingly, for-profit
dialysis facilities have become the norm, with freestand-
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prolific growth [1].
The concern that treatment at for-profit dialysis facilities
may be associated with lower survival rates has been
debated for decades [3-12]. Two comparatively recent
studies [8,12] demonstrated higher mortality rates at for-
profit than at not-for-profit dialysis facilities, leading to
national and international debate [13-17]. The first of
these studies [8] examined a nationally representative
sample of United States patients on hemodialysis at the
end of 1990 and 1993; the second study [12] included
patients from Michigan in 1973 through 1981, and
patients on dialysis in the United States in 1990 and in
1993 through 1997. More recently, mortality was related
to for-profit status in national random samples of patients
receiving hemodialysis therapy in the United States at the
beginning of 1994 through 2000 [18]. In the last of these
studies, while unadjusted analysis showed no differences
in mortality, adjustment for age, demography, cause of
renal disease, and on-therapy clinical benchmarks
showed higher mortality hazards ratio for patients treated
at for-profit facilities [18]. The possibility that dialysis at
for-profit facilities, where 4 of every 5 dialysis patients
receive care [1] may be associated with a survival disad-
vantage has not been examined in more recent cohorts
beginning dialysis therapy in the US. Our study was an
attempt to address this issue.
Methods
Objectives
Our primary objective was to compare the mortality rates
of patients starting hemodialysis at for-profit and at not-
for-profit hemodialysis facilities in the United States
between 1998 and 2003. Secondary objectives included
comparison of clinical benchmarks according to for-profit
or not-for-profit status.
Design
The United States Renal Data System (USRDS) generally
recommends beginning outcome analyses after 90 days
have elapsed since the first dialysis treatment (the 90-day
rule), partly to allow time to establish a stable dialysis
choice and partly because in-center hemodialysis patients
aged less than 65 years cannot bill Medicare for their dial-
ysis treatments until 90 days have elapsed [1]. Thus, for
this study, the starting date was the 91st day after dialysis
inception. Two phases were then constructed, with the
first 3 months of the study (the exposure period) used to
characterize the study population, including assessment
of clinical benchmarks, and subsequent follow-up time
(the outcome period) used to assess mortality.
Study Population
We used the 100% ESRD sample from the Medicare data-
base to select patients who were first dialyzed between
January 1, 1998, and December 31, 2003; had Medicare as
primary payer throughout the exposure period; and were
on hemodialysis at either a for-profit or not-for-profit
dialysis facility at the end of the exposure period.
Patient demographics were obtained from the ESRD Med-
ical Evidence Report (Centers for Medicare & Medicaid
Services [CMS] form CMS-2728-U4), which is filed for all
patients initiating maintenance dialysis. Medicare claims
generated during the exposure period were used as supple-
mentary data sources to identify comorbid conditions.
Comorbid conditions from Medicare Part A institutional
and Part B physician/supplier claims were identified by
International Classification of Diseases, Ninth Revision, Clin-
ical Modification (ICD-9-CM) codes and Current Procedural
Terminology (CPT) codes. Comorbid conditions were con-
sidered present if an affirmative response was present in
the Medical Evidence Report or on Medicare Part A or Part
B claims. Cumulative hospital days and infectious hospi-
talization admissions in the exposure period were also
determined from Medicare inpatient claim files. Clinical
benchmarks, including hemoglobin levels, epoetin doses,
urea reduction ratios, intravenous iron use, and blood
transfusions, were obtained from Medicare institutional
outpatient claims; wait-listing for renal transplant was
obtained from the USRDS database. Vital status was
obtained from the CMS ESRD Death Notification (form
CMS-2746-U3), and renal transplantation from the
USRDS database.
Dialysis facility profit status (for-profit or not-for-profit)
and facility status (freestanding or hospital-based) were
determined from the CMS Annual Facility Survey. Dialysis
facilities can change their profit status, and patients can
change dialysis facilities. We applied the USRDS 60-day
collapsing rule to such changes, namely, that they must
remain in place for at least 60 days to be considered stable
[1].
Analysis
Follow-up began immediately after the exposure period,
and ended at the earliest occurrence of 3 years elapsed,
death, renal transplantation, loss to follow-up, or Decem-
ber 31, 2004. The characteristics of patients receiving dial-
ysis at for-profit and not-for-profit dialysis units were
compared using the chi squared test for categorical varia-
bles and multivariate logistic regression. Cox proportional
hazards regression was used to quantify the mortality haz-
ards ratios. The robust standard error method was used to
account for the possibility of clustering of patients within
dialysis facilities [19]. All analyses were performed using
SAS version 9.1 (SAS Institute, Inc., Cary, NC).Page 2 of 7
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Facility Profit Status
Characteristic All, 100.0% 
N = 205,076
Not-For-Profit, 
20.1% n = 41,307
For-Profit, 79.9% 
n = 163,769
P* AOR For-Profit (95% CI) P†
Facility affiliation < 0.0001
Freestanding 12.9 41.4 98.6 Reference -
Hospital-based 87.1 58.6 1.4 0.01 (0.01–0.01) < 0.0001
Year of dialysis inception < 0.0001
1998 14.7 18.5 13.7 Reference -
1999 15.4 17.6 14.8 1.16 (1.10–1.23) < 0.0001
2000 16.6 17.8 16.3 1.12 (1.06–1.19) < 0.0001
2001 17.0 16.0 17.3 1.06 (1.00–1.12) 0.032
2002 17.8 15.6 18.3 0.87 (0.83–0.92) < 0.0001
2003 18.4 14.4 19.5 0.89 (0.85–0.94) < 0.0001
Age group (years) < 0.0001
≤ 40 7.1 7.7 7.0 Reference -
40 to 65 33.7 32.1 34.1 1.10 (1.04–1.17) 0.002
> 65 59.1 60.2 58.9 1.14 (1.06–1.22) 0.0002
Sex < 0.0001
Male 52.0 53.3 51.7 0.98 (0.95–1.01) 0.280
Female 48.0 46.7 48.3 Reference -
Race < 0.0001
White 62.6 64.9 62.0 Reference -
Black 32.4 29.1 33.2 0.91 (0.88–0.95) 0.001
Other 5.1 5.9 4.8 0.96 (0.90–1.03) 0.297
Body mass index (kg/m2) < 0.0001
< 18.5 5.9 6.4 5.8 0.90 (0.84–0.96) 0.001
18.5 to < 25 38.7 39.0 38.6 Reference -
25 to < 30 28.3 28.2 28.3 1.02 (0.98–1.06) 0.358
≥ 30 27.1 26.4 27.3 1.04 (1.00–1.08) 0.074
Employment status < 0.0001
Employed 10.4 10.6 10.3 Reference -
Unemployed 43.7 41.1 44.4 0.96 (0.91–1.01) 0.093
Retired 45.9 48.4 45.3 0.89 (0.84–0.94) < 0.0001
Cause of ESRD < 0.0001
Diabetes mellitus 48.7 47.6 49.0 Reference -
Hypertension 30.8 28.4 31.4 1.09 (1.05–1.13) < 0.0001
Glomerulonephritis 7.9 9.1 7.6 0.91 (0.86–0.97) 0.002
Other 12.6 14.9 12.0 0.92 (0.87–0.96) 0.0003
Hospitalization (days) < 0.0001
0 65.9 65.6 66.0 Reference -
0 to 5 15.6 15.1 15.7 1.04 (0.99–1.09) 0.110
> 5 18.5 19.3 18.3 1.16 (1.10–1.22) < 0.0001
Infectious hospitalization 10.6 11.1 10.5 0.0011 0.94 (0.89–1.00) 0.036
Atherosclerotic heart 
disease
40.1 42.8 39.4 < 0.0001 0.93 (0.90–0.97) 0.0001
Congestive heart failure 45.0 46.2 44.7 < 0.0001 1.04 (1.00–1.07) 0.043
Stroke or TIA 16.0 16.5 15.9 0.0043 0.98 (0.94–1.02) 0.247
Peripheral vascular disease 27.5 29.4 27.1 < 0.0001 0.99 (0.96–1.03) 0.718
Dysrhythmia 18.8 20.5 18.3 < 0.0001 0.91 (0.87–0.95) < 0.0001
Other cardiac disease 13.1 13.5 13.0 0.0223 1.02 (0.98–1.07) 0.347
COPD 14.0 15.4 13.6 < 0.0001 0.88 (0.84–0.92) < 0.0001
Gastrointestinal disease 4.3 4.7 4.1 < 0.0001 0.96 (0.89–1.04) 0.311
Hepatic disease 8.6 6.8 9.1 < 0.0001 1.51 (1.42–1.60) < 0.0001
Cancer 8.8 9.6 8.6 < 0.0001 0.94 (0.89–0.99) 0.022
Clinical benchmarks
Urea reduction ratio 
(%)
< 0.0001
< 60 8.3 9.3 8.1 0.93 (0.87–0.99) 0.019
60 to < 65 11.7 12.0 11.7 Reference -
65 to < 70 21.7 20.0 22.1 1.20 (1.14–1.27) < 0.0001Page 3 of 7
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In all, 258,774 patients were eligible for analysis. Of these,
facility characteristics were unknown for 26,455. For
another 27,243 patients, information was lacking on date
of birth, sex, race, primary renal disease, body mass index,
or employment status. Hence, the final sample size was
205,076.
After 6 months of dialysis therapy, 79.9% of the sample
was dialyzed at one of 3632 for-profit facilities, and
20.1% at one of 1264 not-for-profit facilities. Table 1
shows the characteristics of the overall study population
and a comparison of patients in for-profit and not-for-
profit facilities. On multivariate analysis, the characteris-
tics associated with therapy at for-profit facilities were as
follows: freestanding units; more recent calendar year; age
≤ 65 years; female sex; non-white race; overweight; fewer
retirees; diabetes and hypertension as primary causes of
renal disease; hospitalization days during the exposure
period; fewer infectious hospitalizations; absence of
atherosclerotic heart disease, dysrhythmia, chronic
obstructive primary disorder, and cancer; and presence of
congestive heart failure and hepatic disease.
Regarding clinical benchmarks after 6 months of dialysis
therapy, on bivariate and multivariate analyses, patients at
for-profit facilities had higher urea reduction ratios,
higher hemoglobin levels (including levels above 12 and
13 g/dL [120 and 130 g/L]), more frequent use of intrave-
nous iron, less frequent use of blood transfusions, and a
lower proportion on the transplant waiting list (Table 1).
The overall crude mortality rate was 25.6 per 100 patient-
years at risk, over a 1.7-year average duration of follow-up.
Unadjusted mortality risk was higher for patients dialyzed
at for-profit facilities (hazards ratio 0.89 compared with
not-for-profit facilities, 95% confidence interval [CI]
0.87–0.92, P < 0.0001). Table 2 shows adjusted mortality
associations from proportional hazards regression mod-
els. Patients dialyzed at for-profit and at not-for-profit
facilities had similar mortality risks (adjusted hazards
ratio [AHR] 1.02, 95% CI 0.99–1.06, P = 0.143). In con-
trast, mortality risk was higher for patients dialyzed at
hospital-based facilities (AHR 1.18, 95% CI 1.14–1.23, P
< 0.0001), compared with freestanding facilities.
Discussion
Using an inception cohort design spanning the years 1998
to 2003, we found similar mortality risks in patients dia-
lyzed at for-profit and at not-for-profit facilities. For-profit
status was associated with each of the clinical benchmarks
studied. Thus, patients at for-profit facilities had higher
urea reduction ratios, higher hemoglobin levels (includ-
ing levels above recommended targets), more frequent
use of intravenous iron, less frequent use of blood trans-
fusions, and a lower proportion on the transplant waiting
list.
70 to < 75 24.3 21.0 25.2 1.22 (1.16–1.29) < 0.0001
≥ 75 20.8 17.2 21.7 1.17 (1.11–1.24) 0.0002
Unknown 13.1 20.4 11.3 - -
Hemoglobin (g/dL)‡ < 0.0001
< 10 7.6 8.9 7.3 0.89 (0.84–0.95) 0.0002
10 to < 11 14.6 15.8 14.3 0.96 (0.92–1.01) 0.080
11 to < 12 28.7 28.7 28.6 Reference -
12 to < 13 24.9 20.3 26.1 1.23 (1.19–1.29) < 0.0001
≥ 13 13.3 9.3 14.3 1.66 (1.57–1.75) < 0.0001
Unknown 10.9 16.9 9.3 - -
Epoetin dose quartiles < 0.0001
(units/month)
< 35,766 22.3 23.3 22.0 Reference -
35,766 to < 58,200 22.4 22.3 22.4 0.96 (0.92–1.00) 0.050
58,200 to < 91,250 22.3 20.0 22.9 1.06 (1.02–1.11) 0.009
≥ 91,250 22.3 17.7 23.4 1.16 (1.10–1.21) < 0.0001
Unknown 10.8 16.7 9.3 - -
Intravenous iron use 71.1 60.1 73.9 < 0.0001 1.23 (1.19–1.27) < 0.0001
Blood transfusion 6.3 6.8 6.2 < 0.0001 0.93 (0.87–0.99) 0.025
On transplant waiting list 2.7 3.6 2.5 < 0.0001 0.75 (0.69–0.82) < 0.0001
Values are percentage of n in column head. AOR, adjusted odds ratio; COPD, chronic obstructive pulmonary disease; ESRD, end-stage renal 
disease; TIA, transient ischemic attack.
*Compared using the χ2 test.
†Using multiple logistic regression, with adjustment for facility affiliation, year of dialysis inception, age group, sex, race, body mass index, 
employment status, cause of ESRD, days of hospitalization, infectious hospitalization, and comorbid conditions.
‡To convert hemoglobin in g/dL to g/L, multiply by 10.
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Table 2: Mortality Hazards Ratios
Characteristic Adjusted* Hazards Ratios (95% CI) P
Facility profit status
Not-for-profit Reference -
For-profit 1.02 (0.99–1.06) 0.143
Facility affiliation
Freestanding Reference -
Hospital-based 1.18 (1.14–1.23) < 0.0001
Year of dialysis inception
1998 Reference -
1999 1.00 (0.97–1.02) 0.707
2000 1.04 (1.01–1.07) 0.003
2001 1.03 (1.00–1.06) 0.035
2002 1.03 (1.00–1.06) 0.046
2003 1.01 (0.98–1.04) 0.724
Age group (years)
≤ 40 Reference -
40 to 65 1.50 (1.44–1.57) < 0.0001
> 65 2.34 (2.23–2.45) < 0.0001
Sex




Black 0.78 (0.77–0.80) < 0.0001
Other 0.76 (0.72–0.81) < 0.0001
Body mass index (kg/m2)
< 18.5 1.21 (1.17–1.25) < 0.0001
18.5 to < 25 Reference -
25 to < 30 0.84 (0.82–0.85) < 0.0001
≥ 30 0.76 (0.75–0.78) < 0.0001
Employment status
Employed Reference -
Unemployed 1.20 (1.15–1.24) < 0.0001
Retired 1.22 (1.18–1.27) < 0.0001
Cause of ESRD
Diabetes mellitus Reference -
Hypertension 0.89 (0.88–0.91) < 0.0001
Glomerulonephritis 0.73 (0.71–0.76) < 0.0001
Other 0.99 (0.97–1.02) 0.490
Hospitalization (days)
0 Reference -
0 to 5 1.13 (1.11–1.16) < 0.0001
> 5 1.54 (1.50–1.57) < 0.0001
Infectious hospitalization 1.13 (1.10–1.16) < 0.0001
Atherosclerotic heart disease 1.06 (1.04–1.08) < 0.0001
Congestive heart failure 1.33 (1.31–1.36) < 0.0001
Stroke or TIA 1.19 (1.17–1.21) < 0.0001
Peripheral vascular disease 1.16 (1.14–1.17) < 0.0001
Dysrhythmia 1.25 (1.23–1.28) < 0.0001
Other cardiac disease 1.07 (1.05–1.10) < 0.0001
COPD 1.23 (1.21–1.26) < 0.0001
Gastrointestinal disease 1.21 (1.17–1.25) < 0.0001
Hepatic disease 1.07 (1.03–1.10) < 0.0001
Cancer 1.44 (1.41–1.48) < 0.0001
COPD, chronic obstructive pulmonary disease; ESRD, end-stage renal disease. TIA, transient ischemic attack
*Using proportional hazards regression with adjustment for for-profit status, facility affiliation, year of dialysis inception, age group, sex, race, body 
mass index, employment status, cause of ESRD, days of hospitalization, infectious hospitalization, and comorbid conditions.
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$67,000 per year in 2002 [1] dialysis is undoubtedly an
expensive therapy. The question of whether profit motives
could compromise care for dialysis patients seems reason-
able. Examining this issue regularly also seems reasona-
ble, given that the treatment of dialysis patients continues
to change rapidly. Recent national studies found associa-
tions between for-profit facility status and patient mortal-
ity different from the associations seen in this study. The
first of these studies examined the question in a nationally
representative sample of patients on hemodialysis in the
United States at the end of 1990 and at the end 1993 [8].
The subset of patients receiving renal replacement therapy
for more than 90 days and less than 1 year was chosen,
and facility profit status was treated as a time-dependent
variable. Treatment at a for-profit dialysis facility was
associated with higher mortality hazards, the point esti-
mate being 20% (95% CI 25–42%) higher than that in
not-for-profit facilities [8].
The second study, a meta-analysis spanning 1973 to 1997,
concluded that relative mortality rates were 8% higher at
private, for-profit than at private, not-for-profit dialysis
facilities [12]. The 8 studies included (4 peer-reviewed
publications, 3 dissertations, 1 letter to an editor) were
heterogeneous with regard to patient selection, covariate
adjustment, and the methods used to generate compara-
tive risk estimates. Twelve studies were not incorporated
in the risk estimate because they included patients on
treatment at public facilities and because the original
authors were unable to perform analyses that excluded
these patients. Interestingly, the overwhelming majority
of patients considered for inclusion in the meta-analysis
came from a single, publicly available dataset, the USRDS
dataset. A de novo analysis of all available patients might
provide useful information, such as homogeneous inclu-
sion criteria and analytical methods, and the ability to
include, exclude, or adjust for potential confounders, such
as dialysis at public or private facilities. One potential
explanation that could harmonize our findings with those
from older studies is the possibility that quality of care has
improved more in for-profit facilities over time than in
not-for-profit or hospital-based facilities.
The most recent study related profit status to mortality in
national random samples of US patients receiving hemo-
dialysis therapy at the beginning of the years 1994
through 2000. Unadjusted analysis showed no mortality
differences, but when adjustment was made for demogra-
phy, cause of renal disease, and, notably, clinical bench-
marks, higher mortality hazards ratios were seen for
therapy at for-profit facilities; as in our study, patients in
for-profit facilities had higher urea reduction ratios and
hemoglobin values than those in not-for-profit facilities
[18].
It is highly implausible that the primary research question
addressed here could ever be addressed with a rand-
omized controlled trial. That being said, the current study
unquestionably suffers from all limitations inherent to
observational designs. Thus, while identification of high-
risk populations is possible, accurate delineation of causal
pathways is not. Despite its limitations, we believe that
this study offers useful information. The sample size was
large, and a national-level population was examined over
several years. Consequently, one methodology was
applied consistently, to all patients, in all years. The study
included relatively contemporary patient cohorts. It used
publicly available data, so others can explore the validity
of the approaches used, now and in the future.
Conclusion
Our findings suggest that, in contemporary hemodialysis
patients in the United States, treatment at for-profit and at
not-for-profit dialysis facilities is associated with similar
mortality rates.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
Study conception and design: RNF, JL, DTG, S–CC, AJC.
Acquisition of data: S–CC, AJC. Analysis and interpreta-
tion of data: RNF, QF, JL, DTG, EDW, S–CC, AJC. Drafting
the manuscript: RNF. Revising the manuscript critically
for important intellectual content: QF, JL, DTG, EDW, S–
CC, AJC.
Acknowledgements
The data reported here have been supplied by the United States Renal Data 
System. This study was performed as a deliverable under Contract No. 
HHSN267200715002C (National Institute of Diabetes and Digestive and 
Kidney Diseases, National Institutes of Health, Bethesda, Maryland). The 
authors thank James Kaufmann, PhD, and Nan Booth, MSW, MPH, for edi-
torial assistance; Dana D. Knopic for help in preparing and submitting the 
manuscript; and Beth Forrest for regulatory assistance in the operation of 
the United States Renal Data System Coordinating Center.
References
1. U.S. Renal Data System: USRDS 2006 Annual Data Report Bethesda,
MD: National Institutes of Health, National Institute of Diabetes and
Digestive and Kidney Diseases; 2006. 
2. Evans RW, Blagg CR, Bryan FA Jr: Implications for health care
policy. A social and demographic profile of hemodialysis
patients in the United States.  JAMA 1981, 245:487-491.
3. Lowrie EG, Hampers CL: The success of Medicare's end-stage
renal-disease program: the case for profits and the private
marketplace.  N Engl J Med 1981, 305:434-438.
4. Held P, Pauly M, Diamond L: Survival analysis of patients under-
going dialysis.  JAMA 1987, 257(5):645-650.
5. Schlesinger M, Cleary PD, Blumenthal D: The ownership of health
facilities and clinical decisionmaking. The case of the ESRD
industry.  Med Care 1989, 27:244-258.
6. Collins AJ, Ma J, Constantini E, Everson S: Dialysis unit and patient
characteristics associated with reuse practices and mortal-
ity: 1989–1993.  J Am Soc Nephrol 1998, 9(11):2108-2117.Page 6 of 7
(page number not for citation purposes)
BMC Nephrology 2008, 9:6 http://www.biomedcentral.com/1471-2369/9/6Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
7. McClellan WM, Soucie JM, Flanders WD: Mortality in end-stage
renal disease is associated with facility-to-facility differences
in adequacy of hemodialysis.  J Am Soc Nephrol 1998, 9:1940-1947.
8. Garg PP, Frick KD, Diener-West M, Powe NR: Effect of the own-
ership of dialysis facilities on patients' survival and referral
for transplantation.  N Engl J Med 1999, 341:1653-1660.
9. Port FK, Wolfe RA, Held PJ: Ownership of dialysis facilities and
patients' survival.  N Engl J Med 2000, 342:1053-1054.
10. Nissenson AR, Owen WF Jr: Ownership of dialysis facilities and
patients' survival.  N Engl J Med 2000, 342:1054-1055.
11. Frankenfield DL, Sugarman JR, Presley RJ, Helgerson SD, Rocco MV:
Impact of facility size and profit status on intermediate out-
comes in chronic dialysis patients.  Am J Kidney Dis 2000,
36:318-326.
12. Devereaux PJ, Schunemann HJ, Ravindran N, Bhandari M, Garg AX,
Choi PT, et al.: Comparison of mortality between private for-
profit and private not-for-profit hemodialysis centers: a sys-
tematic review and meta-analysis.  JAMA 2002, 288:2449-2457.
13. Josefson D: Patients dialysed at for-profit centres do worse.
BMJ 1999, 319:1517.
14. Canadian Health Services Research Foundation: Myth: For-profit
ownership of facilities would lead to a more efficient health-
care system.  Canadian Health Services Research Foundation 2004
[http://www.chsrf.ca/mythbusters/html/myth13_e.php]. 11-19-2004.
Ref Type: Electronic Citation
15. Kalantar-Zadeh K, Mehrotra R, Kopple JD: Quality of care in profit
vs not-for-profit dialysis centers.  JAMA 2003, 289:3089-3090.
16. Blake PG, Mendelssohn DC: Quality of care in profit vs not-for-
profit dialysis centers.  JAMA 2003, 289:3088-3089.
17. Bosch J, Hakim RM, Lazarus JM, McAllister CJ: Quality of care in
profit vs not-for-profit dialysis centers.  JAMA 2003,
289:3087-3088.
18. Szczech LA, Klassen PS, Chua B, Hedayati SS, Flanigan M, McClellan
WM, et al.: Associations between CMS's Clinical Performance
Measures project benchmarks, profit structure, and mortal-
ity in dialysis units.  Kidney Int 2006, 69:2094-2100.
19. Lin D, Wei L: The robust inference for the Cox proportional
hazards model.  J Am Stat Assoc 1989, 84:1074-1078.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2369/9/6/prepubPage 7 of 7
(page number not for citation purposes)
